Key result
High-dose ziprasidone yielded an average QTc interval increase of 3.4 msec, with no cases having an increase >20 msec or reaching the 500 msec threshold of concern.
Why the study?
Does high-dose ziprasidone cause significant QTc interval prolongation in adult inpatients with intractable psychotic symptoms?
Observational (n=15)
No
Does high-dose ziprasidone cause significant QTc interval prolongation in adult inpatients with intractable psychotic symptoms?
High-dose ziprasidone (240-320 mg/day) did not cause clinically significant QTc prolongation in a small cohort of adult inpatients.
Answers are grounded in this paper and cite their sources.
May support high-dose ziprasidone without added QTc concern in select inpatients; leaves open confirmation in randomized studies.
This study examined the effects of high-dose ziprasidone on the electrocardiograms (ECGs) of adult inpatients. This was done in an effort to assess the incremental risk of QTc interval prolongation when using ziprasidone in doses above the maximum dose of 160 mg/day approved by the Food and Drug Administration. We retrospectively examined pre- and post-treatment QTc intervals in 15 subjects at the James A. Haley Veterans Affairs Medical Center who had received high doses of ziprasidone, ranging from 240 to 320 mg/day, due to intractable psychotic symptoms. Pure baseline ECGs were not always attainable, since the majority of the subjects were taking concomitant medications at the time that ziprasidone was initiated. Analysis yielded an average increase of 3.4 msec from pre- to post-treatment, with a maximum post-treatment interval of 452 msec and no cases having a pre- to post- treatment QTc interval increase > 20 msec. These findings are statistically insignificant and do not approach the 500 msec threshold of concern. This study suggests that high-dose ziprasidone does not have a significant incremental effect on QTc interval prolongation in certain subsets of patients. However, it does not rule out the possibility that ziprasidone could have deleterious effects in higher risk populations or that ziprasidone could have rare, idiosyncratic cardiogenic effects. Limitations of the study are identified and recommendations for future research are presented.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2004) conducted an observational in Intractable psychotic symptoms (n=15). High-dose ziprasidone vs. Pre-treatment baseline was evaluated on QTc interval changes from pre- to post-treatment (average increase of 3.4 msec). High-dose ziprasidone yielded an average QTc interval increase of 3.4 msec, with no cases having an increase >20 msec or reaching the 500 msec threshold of concern.
Synapse has enriched 10 related papers. Consider them for comparative context: